Screener
Jazz Pharmaceuticals JAZZ Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One) at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
FAQ
- What is Jazz Pharmaceuticals's finite-lived intangible assets - expected amortization expense (year one)?
- Jazz Pharmaceuticals (JAZZ) reported finite-lived intangible assets - expected amortization expense (year one) of $578.5M in Q1 2026.
- How has Jazz Pharmaceuticals's finite-lived intangible assets - expected amortization expense (year one) changed year-over-year?
- Jazz Pharmaceuticals's finite-lived intangible assets - expected amortization expense (year one) decreased by 8.3% year-over-year, from $630.66M to $578.5M.
- What does finite-lived intangible assets - expected amortization expense (year one) mean?
- This metric forecasts the amortization expense expected to be recognized in the upcoming fiscal year for intangible assets with finite useful lives. It provides visibility into the non-cash earnings impact of previously acquired intangible assets. Analysts use this to refine future earnings projections and cash flow models.
Ask your AI about Jazz Pharmaceuticals's finite-lived intangible assets - expected amortization expense (year one).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude